EUVIMEDEUVIMED entdecken
Crossref

Lisdexamfetamine: an over(re)view

Mariana Silva‐Carvalho, Diana Dias da Silva, Daniel José Barbosa, Ricardo Jorge Dinis‐Oliveira

Proceedings of Research and Practice in Allied and Environmental Health · 28.08.2026

DOI: 10.26537/prpaeh.v3i2.6150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of Research and Practice in Allied and Environmental Health, erschienen am 28.08.2026. Verfasst von Mariana Silva‐Carvalho und 3 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lisdexamfetamine (LDX), a prodrug of d-amphetamine, is a pharmaceutical used in the treatment of neuropsychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD) (1).

Objective

Herein we aimed to comprehensively review LDX pharmacokinetics, pharmacodynamics, clinical efficacy, safety profile, and forensic implications.

Methods

A literature search was conducted in PubMed without a limitation period using the keywords LDX, pharmacokinetics/dynamics, clinical use and efficiency, among others related. All types of articles were included.

Results

LDX undergoes rapid absorption via peptide transporter 1 (PepT1) in the small intestine, achieving Cmax within 1–2h (2-5), and is hydrolyzed in erythrocytes by an unidentified aminopeptidase, into d-amphetamine and l-lysine (5, 6). Excretion occurs primarily via urine (96.4%), with minimal fecal elimination (0.3%) (2). Pharmacokinetic studies indicate that LDX does not significantly alter the activity of CYP1A2, CYP2D6, and CYP3A4 (7), suggesting low potential for drug-drug interactions. Its stimulant activity results from trace amine-associated receptor 1 (TAAR1) activation, monoamine oxidase (MAO) inhibition, and reverse transport of the vesicular monoamine transporter 2 (VMAT2), dopamine transporter (DAT), norepinephrine transporter (NAT), and serotonin transporter (SERT), increasing dopamine levels in synaptic cleft (1, 8). Common adverse effects of LDX include dizziness, somnolence, appetite suppression, headache, nausea, and fatigue (9). Concerns regarding growth suppression arise mainly in the first year of treatment and diminishing thereafter (9, 10). Although LDX exhibits a lower reinforcing potential than d-amphetamine (11), supra-therapeutic doses may induce similar abuse liability and toxicity. However, its higher lethal dose threshold (five times that of amphetamines) reduces overdose risk (12).

Conclusions

LDX therapeutic efficacy in ADHD is well-established, with superior outcomes relative to other stimulant medications. In forensic context, differentiating between therapeutic and illicit consumption remains a critical challenge. Given its potential applications beyond ADHD, further large-scale studies are warranted to elucidate the full scope of LDX’s pharmacological and clinical utility.

Schlagwörter

lisdexamfetamineattention deficit hyperactivity disorderpharmacokineticspharmacodynamicsPepT1TAAR1monoamine transportersdrug-drug interactionsadverse effectsgrowth inhibition

Zitieren

APA

Silva‐Carvalho, M., Silva, D. D. D., Barbosa, D. J., & Dinis‐Oliveira, R. J. (2026). Lisdexamfetamine: an over(re)view. Proceedings of Research and Practice in Allied and Environmental Health. https://doi.org/10.26537/prpaeh.v3i2.6150

Vancouver

Silva‐Carvalho M, Silva DDD, Barbosa DJ, Dinis‐Oliveira RJ. Lisdexamfetamine: an over(re)view. Proceedings of Research and Practice in Allied and Environmental Health. 2026. doi:10.26537/prpaeh.v3i2.6150

BibTeX
@article{SilvaCarvalho2026,
  author = {Silva‐Carvalho, Mariana and Silva, Diana Dias da and Barbosa, Daniel José and Dinis‐Oliveira, Ricardo Jorge},
  title = {Lisdexamfetamine: an over(re)view},
  journal = {Proceedings of Research and Practice in Allied and Environmental Health},
  year = {2026},
  doi = {10.26537/prpaeh.v3i2.6150}
}
Kostenlos starten →